BioCentury
ARTICLE | Politics & Policy

ICER aims to define HTA approach to gene therapies

January 23, 2019 11:08 PM UTC

The Institute for Clinical and Economic Review is taking the lead in defining the global health technology assessment (HTA) process for potentially curative treatments such as gene therapies, strengthening its position as the de facto HTA in the U.S.

In a new collaboration with National Institute for Health and Care Excellence (NICE) in the U.K. and the Canadian Agency for Drugs and Technologies in Health (CADTH), ICER will test methods for evaluating the cost-effectiveness value of potential cures to guide recommendations for value-based price benchmarks. ...